NEW YORK (WFXR) — Pfizer issued a nationwide blood pressure recall because the presence of nitrosamine is above the Acceptable Daily Intake (ADI) level.
The recall is for Accuretic tablets and two generics distributed by Greenstone — quinapril and hydrochlorothiazide and quinapril HCI/hydrochlorothiazide.
Pfizer will pull six lots of Accuretic tablets, one lot of quinapril and hydrochlorothiazide tablets, and four lots of quinapril HCI/hydrochlorothiazide tablets.
Health officials say you can find nitrosamines in water and foods, cured and grilled meats, dairy products, and vegetables. However, people exposed to the above ADI levels of nitrosamines for a long period of time can increase the risk of cancer.
These products are used to help treat hypertension and lower blood pressure in people to decreases the risk of deadly and non-deadly cardiovascular events, strokes, and myocardial infarctions. Pfizer recommends patients who take this medication should talk to their doctors about alternative treatment options.
The recalled products are from November 2019 to March 2022 and were distributed throughout the United States and Puerto Rico. Below are the products on the recall list.
- Accuretic™ (quinapril HCl/hydrochlorothiazide) tablets, 10/12.5 mg
- Accuretic™ (quinapril HCl/hydrochlorothiazide) tablets, 20/12.5 mg
- Accuretic™ (quinapril HCl/hydrochlorothiazide) tablets, 20/25 mg
| NDC | Lot Number | Expiration Date | Strength | Configuration/Count |
| 0071-3112-23 | FG5379 | 08/2024 | 10/12.5 mg | 1 x 90 count bottle |
| 0071-0222-23 | EA6686 | 04/2022 | 10/12.5 mg | 1 x 90 count bottle |
| 0071-5212-23 | FG5381 | 08/2024 | 20/12.5 mg | 1 x 90 count bottle |
| 0071-0220-23 | EA6665 | 04/2022 | 20/12.5 mg | 1 x 90 count bottle |
| 0071-0220-23 | CN0640 | 04/2022 | 20/12.5 mg | 1 x 90 count bottle |
| 0071-0223-23 | ET6974 | 02/2023 | 20/25 mg | 1 x 90 count bottle |
- quinapril and hydrochlorothiazide tablets, 20/25 mg
- quinapril HCl/hydrochlorothiazide tablets, 20/12.5 mg
- quinapril HCl/hydrochlorothiazide tablets, 20/25 mg
| NDC | Lot Number | Expiration Date | Strength | Configuration/Count |
| 59762-5225-9 | FE3714 | 02/2023 | 20/25 mg | 1 x 90 count bottle |
| 59762-0220-1 | DN6931 | 03/2023 | 20/12.5 mg | 1 x 90 count bottle |
| 59762-0220-1 | ED3904 | 03/2023 | 20/12.5 mg | 1 x 90 count bottle |
| 59762-0220-1 | ED3905 | 03/2023 | 20/12.5 mg | 1 x 90 count bottle |
| 59762-0223-1 | DP3414 | 02/2023 | 20/25 mg | 1 x 90 count bottle |
Pfizer stated that wholesalers and distributors with any of these products should stop use and distribution and immediately quarantine the product.
For more information about this recall head to the Pfizer website here.
More Stories
Most medical college students get worried abortion rules will ‘hinder their foreseeable future care’
Edinburgh to host supercomputer process that may perhaps advance drugs, AI and strength
Drug-microbiota interactions: an emerging priority for precision medicine